<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947384</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300006686</org_study_id>
    <nct_id>NCT04947384</nct_id>
  </id_info>
  <brief_title>Pulmonary Vascular Hemodynamics Before and After Mitral Valve Procedures</brief_title>
  <official_title>Pulmonary Vascular Hemodynamics Before and After Mitral Valve Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this proposal is to study circulating and echocardiographic markers of&#xD;
      pulmonary vascular and right ventricular remodeling in patients with a WHO-2 diagnosis of&#xD;
      pulmonary hypertension after mitral valve procedures. The investigators are proposing the&#xD;
      study will be impactful for the early detection and prediction and of residual pulmonary&#xD;
      hypertension (PH) that would otherwise be undetected and fatal with no curative treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll 3 groups: Group 1: Patients with established WHO-2 diagnosis of&#xD;
      PH undergoing open and interventional mitral valve procedures. Group 2: Patients with no PH&#xD;
      undergoing open and interventional mitral valve procedures. Group 3: Patients with&#xD;
      established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. Groups&#xD;
      2 and 3 will serve as controls. All procedures will be performed at the main UAB Hospital&#xD;
      cardiac surgical operating rooms and at the cardiac angiographic suites. The investigators&#xD;
      will collect a total of 3 blood samples; the first sample will be obtained on arterial&#xD;
      cannulation before the initiation of the intervention, the second sample will be collected&#xD;
      upon the end of the procedure prior to leaving the procedure room, and the third sample will&#xD;
      be collected on the day of discharge from the hospital. A comprehensive echocardiogram at the&#xD;
      3 corresponding time points of the blood samples obtained; before, and after the intervention&#xD;
      and before discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>From baseline through one year</time_frame>
    <description>observation of tissue anomalies in target patients</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with moderate mitral valve disease, undergoing interventions</arm_group_label>
    <description>Patients with established WHO-2 diagnosis of PH undergoing open and interventional mitral valve procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing mitral valve interventions without pulmonary hypertension</arm_group_label>
    <description>Patients with no PH undergoing open and interventional mitral valve procedures. This group will serve as a control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with precapillary pulmonary hypertension scheduled for right heart catheterization</arm_group_label>
    <description>Patients with established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. This group will serve as a control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>To discern micro-RNA specific for right and left heart induced PH</intervention_name>
    <description>While undergoing other procedures, the investigators will be collecting a total of three blood samples. The first sample will be obtained on arterial cannulation before the initiation of the intervention, the second sample will be collected upon the end of the procedure prior to leaving the procedure room, and the third sample will be collected on the day of discharge from the hospital.</description>
    <arm_group_label>Patients undergoing mitral valve interventions without pulmonary hypertension</arm_group_label>
    <arm_group_label>Patients with moderate mitral valve disease, undergoing interventions</arm_group_label>
    <arm_group_label>Patients with precapillary pulmonary hypertension scheduled for right heart catheterization</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients undergoing mitral valve procedures at the University of Alabama at&#xD;
        Birmingham main hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 18 years/old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ejection fraction (EF) &lt; 35%&#xD;
&#xD;
          -  Patients with severe tricuspid valve regurgitation&#xD;
&#xD;
          -  Transplant patients&#xD;
&#xD;
          -  Patients scheduled for ventricular assist devices&#xD;
&#xD;
          -  Patients with a diagnosis of heart failure with preserved ejection fraction&#xD;
&#xD;
          -  Any aortic valvular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Zaky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LaShun Horn, MS</last_name>
    <phone>2059962606</phone>
    <email>llhorn@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>LaShun Horn, MS</last_name>
      <phone>205-996-2606</phone>
      <email>llhorn@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmed Zaky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Ahmed Zaky</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

